Table 3 Indications for WBMRI introduced during the course of MBC re-assessment which were previously assessed with CT or FDG-PET/CT
Indications for WBMRI | N (%) | |
|---|---|---|
Clinical symptoms (e.g. bone pain, limb weakness) | 20 (24.7) | |
Indeterminate findings on other imaging modalities | 16 (19.8) | |
Rise in tumour markers | 8 (9.9) | |
Bone-only disease which was difficult to assess with CT | 7 (8.6) | |
Pseudocirrhotic liver | 4 (4.9) | |
Deranged blood results (e.g. anaemia, pancytopaenia, hypercalcaemia) | 4 (4.9) | |
Recommended by radiologist or at the multidisciplinary team meeting | 3 (3.7) | |
Other (e.g. CT/FDG-PET/CT declined by patients due to radiation concerns, clinical trial entry requirements) | 7 (8.6) | |
Combination of indications: Rise in CA 15–3 tumour marker plus: | clinical symptoms | 8 (9.9) |
indeterminate findings on other imaging modalities | 1 (1.2) | |
deranged blood results | 2 (2.4) | |
recommended by radiologist | 1 (1.2) | |